| Oct 1 |
Ascendis Pharma submits sBLA for growth hormone deficiency therapy
|
| Oct 1 |
High Growth Tech Stocks To Watch In October 2024
|
| Sep 30 |
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
|
| Sep 30 |
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
|
| Sep 25 |
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
|
| Sep 22 |
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
|
| Sep 22 |
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
|
| Sep 20 |
Ascendis Pharma prices $300M equity offering
|
| Sep 20 |
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
|
| Sep 18 |
Ascendis Pharma proposed public offering of ADSS
|
